{"organizations": [], "uuid": "7096f469001cad6ae2dec137c4837ab159603aed", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/idUSL8N1Q9138", "country": "US", "domain_rank": 408, "title": "BRIEF-Morphosys And Galapagos Present Results From Phase 1 Study With Mor106", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-19T10:04:00.000+02:00", "replies_count": 0, "uuid": "7096f469001cad6ae2dec137c4837ab159603aed"}, "author": "", "url": "https://www.reuters.com/article/idUSL8N1Q9138", "ord_in_thread": 0, "title": "BRIEF-Morphosys And Galapagos Present Results From Phase 1 Study With Mor106", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "morphosys ag", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 19 (Reuters) - MORPHOSYS AG:\n* SAID ON SATURDAY MORPHOSYS AND GALAPAGOS PRESENT RESULTS FROM A PHASE 1 STUDY WITH MOR106 IN ATOPIC DERMATITIS AS LATE-BREAKING ABSTRACT\n* IN THE STUDY, MOR106 WAS GENERALLY WELL TOLERATED IN ATOPIC DERMATITIS(AD)PATIENTS\n* 83% OF PATIENTS (5 OUT OF 6) AT THE HIGHEST DOSE REACHED AT LEAST 50% IMPROVEMENT PER THE ATOPIC DERMATITIS AREA AND SEVERITY INDEX (EASI-50) AT WEEK 4\n* POOLED DATA ACROSS ALL DOSE COHORTS SHOWED 72% IMPROVEMENT OF AD SYMPTOMS AT WEEK 12 COMPARED TO BASELINE IN PATIENTS TREATED WITH MOR106\n* PHASE 2 DEVELOPMENT OF MOR106 PLANNED TO BE INITIATED IN FIRST HALF OF 2018\nSource text for Eikon:\nFurther company coverage: (Gdynia Newsroom)\n ", "external_links": [], "published": "2018-02-19T10:04:00.000+02:00", "crawled": "2018-02-19T10:27:48.000+02:00", "highlightTitle": ""}